Your browser doesn't support javascript.
loading
Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study.
Kuon, Jonas; Blasi, Miriam; Unsöld, Laura; Vogt, Jeannette; Mehnert, Anja; Alt-Epping, Bernd; van Oorschot, Birgitt; Sistermanns, Jochen; Ahlborn, Miriam; Ritterbusch, Ulrike; Stevens, Susanne; Kahl, Christoph; Ruellan, Anne; Matthias, Kathrin; Kubin, Thomas; Stahlhut, Kerstin; Heider, Andrea; Lordick, Florian; Thomas, Michael.
Afiliação
  • Kuon J; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany. Jonas.Kuon@med.uni-heidelberg.de.
  • Blasi M; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
  • Unsöld L; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
  • Vogt J; Department of Medicine-2 (Oncology, Gastroenterology, Pulmonology, and Infectious Diseases), and University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, HepatologyLeipzig, Germany.
  • Mehnert A; Department of Medical Psychology and Medical Sociology, University Hospital Leipzig, Leipzig, Germany.
  • Alt-Epping B; Department of Palliative Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • van Oorschot B; Interdisciplinary Department of Palliative Medicine, University Hospital Würzburg, Würzburg, Germany.
  • Sistermanns J; Department of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.
  • Ahlborn M; Department of Oncology and Hematology, Klinikum Braunschweig, Braunschweig, Germany.
  • Ritterbusch U; Westdeutsches Tumorzentrum, University Hospital Essen, Essen, Germany.
  • Stevens S; Department of Internistic Oncology, Kliniken Essen Mitte, Essen, Germany.
  • Kahl C; Department of Hematology, , Oncology and Palliative Care, Klinikum Magdeburg, Magdeburg, Germany.
  • Ruellan A; Department of Oncology, Hematology and Palliative Care, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
  • Matthias K; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Kubin T; Department of Haematology Oncology and Palliative Care, Klinikum Traunstein, Traunstein, Germany.
  • Stahlhut K; Ambulatory of Haematology Oncology and Palliative Care, Immanuel Klinik Und Poliklinik Rüdersdorf, Rüdersdorf bei Berlin, Germany.
  • Heider A; Department of Medicine 3, Klinikum Leverkusen, Leverkusen, Germany.
  • Lordick F; Department of Medicine 2 (Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Disease), University Cancer Center Leipzig (UCCL), University of Leipzig Medical Center, Leipzig, Germany.
  • Thomas M; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg TLRC-H, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Support Care Cancer ; 30(4): 3131-3140, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34877613
PURPOSE: The purpose of this study is to investigate changes over time in quality of life (QoL) in incurable lung cancer patients and the impact of determinants like molecular alterations (MA). METHODS: In a prospective, longitudinal, multicentric study, we assessed QoL, symptom burden, psychological distress, unmet needs, and prognostic understanding of patients diagnosed with incurable lung cancer at the time of the diagnosis (T0) and after 3 (T1), 6 (T2) and 12 months (T3) using validated questionnaires like FACT-L, National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT), PHQ-4, SCNS-SF-34, and SEIQoL. RESULTS: Two hundred seventeen patients were enrolled, 22 (10%) with reported MA. QoL scores improved over time, with a significant trend for DT, PHQ-4, and SCNS-SF-34. Significant determinants for stable or improving scores over time were survival > 6 months, performance status at the time of diagnosis, and presence of MA. Patients with MA showed better QoL scores (FACT-L at T1 104.4 vs 86.3; at T2 107.5 vs 90.0; at T3 100.9 vs 92.8) and lower psychological distress (NCCN DT at T1 3.3 vs 5; at T2 2.7 vs 4.5; at T3 3.7 vs 4.5; PHQ-4 at T1 2.3 vs 4.1; at T2 1.7 vs 3.6; at T3 2.2 vs 3.6), but also a worsening of the scores at 1 year and a higher percentage of inaccurate prognostic understanding (27 vs 17%) compared to patients without MA. CONCLUSION: Patients with tumors harboring MA are at risk of QoL deterioration during the course of the disease. Physicians should adapt their communication strategies in order to maintain or improve QoL.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Support Care Cancer Assunto da revista: NEOPLASIAS / SERVICOS DE SAUDE Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha